Adeno-associated virus (AAV)-mediated systemic administration of microdystrophin, which functionally substitutes for dysfunctional dystrophin in DMD, demonstrates amelioration of muscle pathology, enhancement of contractile force, and attenuation of cardiomyopathy in preclinical models. Here, DMD is linked to Duchenne muscular dystrophy.